UnitedHealth Siphons Billions in Medicare Premiums Using Secret 'Spread Pricing' Tactics

In July 2024, an Federal Trade Commission (FTC) interim report confirmed what independent pharmacists have alleged for a decade: the nation’s largest Pharmacy Benefit Managers (PBMs) are functioning as a 'black box' that drives up drug costs while squeezing local businesses out of existence. At the center of this investigation is OptumRx, a subsidiary of UnitedHealth Group (UHG). UHG, which reported a staggering $371.6 billion in total revenue in 2023, has leveraged its vertical integration to dominate the prescription drug market, with Optum alone contributing $226.6 billion to that total.

To understand the mechanism of this extraction, one must look at the 'spread.' [Spread Pricing] is the practice where a PBM charges a health plan—in this case, taxpayer-funded Medicare Part D—significantly more for a generic drug than the amount it actually pays to the pharmacy that dispenses it. According to the FTC findings, OptumRx frequently steers patients toward its own affiliated pharmacies while reimbursing independent competitors at rates that fall below the pharmacy's cost of acquisition. This creates a dual-revenue stream for UHG: they profit from the government’s overpayment and from the destruction of their competition.

[Pharmacy Benefit Manager (PBM)] is a third-party administrator of prescription drug programs that negotiates prices with manufacturers, develops formularies, and processes pharmacy claims. While mainstream media often portrays PBMs as negotiators that lower costs for consumers, the financial reality inside UHG suggests otherwise. By owning both the insurer (UnitedHealthcare) and the PBM (OptumRx), UHG creates a circular money flow. Taxpayer dollars flow from the Centers for Medicare & Medicaid Services (CMS) to UnitedHealthcare. UnitedHealthcare then pays its own subsidiary, OptumRx, to manage benefits. This allows UHG to shift profits from the highly regulated insurance side to the largely unregulated PBM side, effectively bypassing Medical Loss Ratio (MLR) requirements that limit how much profit an insurer can keep from premiums.

This system is protected by a massive legislative firewall. According to OpenSecrets data, UnitedHealth Group spent $10.2 million on federal lobbying during the 2023-2024 cycle. This spending coincided precisely with the stalling of the PBM Transparency Act (S.127). The bill, which boasts rare bipartisan support, would ban spread pricing and require PBMs to report the actual costs and rebates they receive. Currently, the bill remains stuck in the Senate Committee on Commerce, Science, and Transportation. FEC filings show that members of this committee have been primary targets for UHG’s political action committee (PAC) contributions, ensuring the 'black box' remains closed to federal auditors.

Beyond spread pricing, OptumRx maintains high drug costs through the use of 'rebate walls.' [Rebate Wall] is a contractual arrangement where a PBM receives significant administrative fees and rebates from a drug manufacturer in exchange for giving that manufacturer’s high-priced brand-name drug 'preferred' status on a formulary. This practice actively blocks lower-cost biosimilars from reaching patients. For instance, while lower-cost insulin alternatives have entered the market, OptumRx’s internal incentives favor high-list-price products because the PBM’s fees are often calculated as a percentage of that list price. The result? A senior on Medicare pays a co-insurance percentage based on a $300 list price, even if the PBM’s net cost after secret rebates is only $40.

To further obscure these trails, UHG utilizes offshore entities like Emisar Pharma Services. Based in Ireland, this Group Purchasing Organization (GPO) allows OptumRx to negotiate manufacturer rebates outside the immediate jurisdiction of U.S. regulators. This 'GPO' layer adds another veil of complexity, making it nearly impossible for CMS to track whether the rebates negotiated with taxpayer money are being passed back to the Medicare program or are being retained as corporate profit.

For the average American, this isn't just corporate accounting—it is a direct hit to their health and wallet. When OptumRx reimbursements to independent pharmacies fall below the cost of the drug, those pharmacies close. This has led to the rise of 'pharmacy deserts,' particularly in rural areas where the only remaining option is Optum’s own mail-order service. Seniors lose the personalized care of a local pharmacist and are forced into a system that prioritizes UHG’s quarterly earnings over patient access. For the taxpayer, it means billions in federal Medicare funds are being diverted from actual healthcare into the $10.2 million lobbying machine designed to keep this system legal.

At Gen Us, we believe in following the receipts. You can use our Politician Tracker to see which members of the Senate Commerce Committee received contributions from UnitedHealth Group’s PAC during the S.127 deliberations. Transparency shouldn't be a policy goal; it should be the standard.